Proposed Changes to Best Price and Market Dynamics

This technical report discusses the proposed changes to the Best Price definition under the Medicaid Drug Rebate Program (MDRP) as outlined in the 2023 proposed rule titled 'Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.' The report explains that the proposed amendments would require manufacturers to aggregate all price concessions provided throughout the supply chain for a single unit of a drug, which could increase Medicaid rebate liability for certain drug classes, including antipsychotics, multiple sclerosis, and oncology. The analysis indicates that the statutory basic rebate for these drugs could increase by 17%-21%. The report details potential market responses from stakeholders, including manufacturers, payers, and providers, which may involve re-evaluating commercial payer rebates and restructuring supply chain discounts. It also highlights the implications of these changes on contracting arrangements and market strategies, particularly in light of other concurrent policy shifts in drug pricing.